Silverback Therapeutics (SBTX) presents at ESMO Congress 2021

SBT6050-101: Phase 1/1B Interim Clinical Study Update Investor Presentation at the European Society of Medical Oncology 2021 September 16, 2021 Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any ...